Abstract:A diverse group of RNA viruses have the ability to gain access to the central nervous system (CNS) and cause severe neurological disease. Current treatment for people with this type of infection is generally limited to supportive care. To address the need for reliable antivirals, we utilized a strategy of lethal mutagenesis to limit virus replication. We evaluated ribavirin (RBV), favipiravir (FAV) and N 4 -hydroxycytidine (NHC) against La Crosse virus (LACV), which is one of the most common causes of pediatric arboviral encephalitis cases in North America and serves as a model for viral CNS invasion during acute infection. NHC was approximately 3 to 170 times more potent than RBV or FAV in neuronal cells. Oral administration of molnupiravir (MOV), the prodrug of NHC, decreased neurological disease development (assessed as limb paralysis, ataxia and weakness, repeated seizures, or death) by 31% (4 mice survived out of 13) when treatment was started on the day of infection. MOV also reduced disease by 23% when virus was administered intranasally (IN). NHC and MOV produced less fit viruses by incorporating predominantly G to A or C to U mutations. Furthermore, NHC also inhibited virus production of two other orthobunyaviruses, Jamestown Canyon virus and Cache Valley virus. Collectively, these studies indicate that NHC/MOV has therapeutic potential to inhibit viral replication and subsequent neurological disease caused by orthobunyaviruses and potentially as a generalizable strategy for treating acute viral encephalitis. Mutagenic ribonucleosides can be viewed as broadly acting antivirals against RNA viruses. These viruses have small genomes of essential genes and thus are susceptible to enhanced mutation rates as an antiviral strategy. Here we show that the mutagenic ribonucleoside N 4 -hydroxycytidine (NHC) and its prodrug molnupiravir are active against the negative strand bunyavirus La Crosse Virus. Loss of viral infectivity was proportional to the density of mutations induced by NHC. Using a mouse model, we showed that oral administration of molnupiravir attenuated encephalitis caused by La Crosse virus and resulted in reduced virus titers and less fit virus in the brain. This treatment approach should be widely applicable to acute RNA virus diseases, especially those with high morbidity and an absence of other treatment options.

Consecutive alternating administration as an effective anti-coxsackievirus B3 in vivo treatment scheme

Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes As an in Vitro Model for Coxsackievirus B3-Induced Myocarditis and Antiviral Drug Screening Platform

Efficacy of an isoxazole-3-carboxamide analog of pleconaril in mouse models of Enterovirus-D68 and Coxsackie B5

Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice

Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9

Development of broad-spectrum enterovirus antivirals based on quinoline scaffold

Development of Enterovirus Antiviral Agents That Target the Viral 2C Protein

From the "One-Molecule, One-Target, One-Disease" Concept towards Looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) Infections

Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein

Novel antivirals for severe enterovirus infection in immunocompromised hosts; a case series

In vitro synergistic antiviral activity of repurposed drugs against enterovirus 71

In-vitro antiviral activity of doxepin hydrochloride against group B coxsackievirus

N 4 -Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses

CUR-N399, a PI4KB inhibitor, for the treatment of Enterovirus A71 infection

New Potent EV-A71 Antivirals Targeting Capsid.

Longitudinal Monitoring of the Effects of Anti-Adenoviral Treatment Regimens in a Permissive In Vivo Model

SAR Analysis of Novel Coxsackie virus A9 Capsid Binders

Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A.

Pharmacological Characterization of the Mechanism of Action of R523062 , a Promising Antiviral for Enterovirus D68

Inhibition of coxsackievirus infection in cardiomyocytes by small dsRNA targeting its cognate coxsackievirus adenovirus receptor

Antiviral treatment of cytomegalovirus infection: an update